enGene (ENGN) Corporate presentation summary

Disease landscape and unmet need

• Non-muscle invasive bladder cancer (NMIBC) accounts for 75–80% of bladder cancer diagnoses, with ~72,000 new US cases annually and a highly recurrent, slowly progressing course.

• Standard BCG therapy faces chronic shortages and poor long-term tolerability, with 50% recurrence at 2 years and significant quality-of-life impacts from radical cystectomy.

• About 80% of NMIBC patients are treated in community urology practices, which are strained by high patient volume and limited resources.

• FDA guidance highlights the need for new therapies that preserve the bladder and improve long-term outcomes.

Product overview and platform

• Detalimogene voraplasmid is a non-viral gene therapy using the proprietary DDX platform, enabling delivery of large genetic cargo with low immunogenicity and low cost of goods.

• The therapy is designed for seamless integration into urology practices, requiring minimal handling, storage at 2–8°C, and administration by nurses in exam rooms.

• Detalimogene activates both innate and adaptive immune responses locally in the bladder, delivering plasmid DNA encoding genes that stimulate the RIG-I pathway and IL-12 expression.

• Manufacturing is industrial-scale, with readily available components, long storage times, and low risk of supply shortages.

Clinical development and efficacy

• The pivotal LEGEND study enrolled 125 BCG-unresponsive, high-risk NMIBC patients with CIS; protocol amendments aligned with standard of care and improved patient eligibility and assessment rigor.

• Post-amendment, the 6-month complete response (CR) rate was 62% (CI: 46–76%), with a 3-month CR rate of 56% and any-time CR rate of 63%.

• Pre-amendment, the 6-month CR rate was 41% (CI: 25–59%), showing marked improvement after protocol changes.

• Detalimogene's efficacy is competitive with other novel therapies, with 6-month CR rates in the range of approved products.